Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) - HC Wainwright upped their Q1 2025 earnings per share (EPS) estimates for shares of Mineralys Therapeutics in a research report issued on Wednesday, April 2nd. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings per share of ($0.90) for the quarter, up from their previous forecast of ($1.13). HC Wainwright has a "Buy" rating and a $42.00 price target on the stock. The consensus estimate for Mineralys Therapeutics' current full-year earnings is ($4.23) per share. HC Wainwright also issued estimates for Mineralys Therapeutics' Q2 2025 earnings at ($0.88) EPS, Q3 2025 earnings at ($0.87) EPS, Q4 2025 earnings at ($0.86) EPS, FY2025 earnings at ($3.50) EPS, FY2026 earnings at ($3.23) EPS, FY2027 earnings at ($3.46) EPS, FY2028 earnings at ($1.58) EPS and FY2029 earnings at $1.36 EPS.
Other analysts have also issued reports about the stock. The Goldman Sachs Group lowered their price target on shares of Mineralys Therapeutics from $28.00 to $24.00 and set a "buy" rating on the stock in a research report on Thursday, February 13th. Guggenheim reissued a "buy" rating on shares of Mineralys Therapeutics in a research report on Monday, February 24th.
Get Our Latest Stock Report on Mineralys Therapeutics
Mineralys Therapeutics Stock Performance
NASDAQ:MLYS traded up $1.21 during mid-day trading on Monday, hitting $13.40. 848,809 shares of the company's stock traded hands, compared to its average volume of 409,065. The company has a market cap of $841.32 million, a PE ratio of -3.68 and a beta of -0.39. The firm's 50 day simple moving average is $12.21 and its 200 day simple moving average is $12.31. Mineralys Therapeutics has a 1 year low of $8.24 and a 1 year high of $18.38.
Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last released its quarterly earnings results on Wednesday, February 12th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.00) by $0.02.
Institutional Investors Weigh In On Mineralys Therapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. GAMMA Investing LLC lifted its position in Mineralys Therapeutics by 9,602.2% during the first quarter. GAMMA Investing LLC now owns 8,829 shares of the company's stock worth $140,000 after buying an additional 8,738 shares during the period. Wellington Management Group LLP increased its stake in shares of Mineralys Therapeutics by 43.0% during the 4th quarter. Wellington Management Group LLP now owns 91,529 shares of the company's stock valued at $1,127,000 after acquiring an additional 27,531 shares during the last quarter. Polar Asset Management Partners Inc. lifted its holdings in shares of Mineralys Therapeutics by 144.7% during the 4th quarter. Polar Asset Management Partners Inc. now owns 99,100 shares of the company's stock worth $1,220,000 after acquiring an additional 58,600 shares during the period. Tema Etfs LLC purchased a new position in shares of Mineralys Therapeutics during the 4th quarter worth about $1,102,000. Finally, Stempoint Capital LP acquired a new stake in shares of Mineralys Therapeutics in the fourth quarter worth approximately $4,925,000. Hedge funds and other institutional investors own 84.46% of the company's stock.
Insider Buying and Selling at Mineralys Therapeutics
In other news, insider David Malcom Rodman sold 55,771 shares of the business's stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $15.76, for a total value of $878,950.96. Following the completion of the transaction, the insider now owns 116,704 shares of the company's stock, valued at $1,839,255.04. The trade was a 32.34 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Samsara Biocapital Gp, Llc acquired 600,000 shares of Mineralys Therapeutics stock in a transaction that occurred on Thursday, March 13th. The shares were purchased at an average cost of $13.50 per share, for a total transaction of $8,100,000.00. Following the purchase, the insider now directly owns 5,674,916 shares of the company's stock, valued at approximately $76,611,366. This trade represents a 11.82 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have sold 84,861 shares of company stock worth $1,142,937. Corporate insiders own 33.24% of the company's stock.
About Mineralys Therapeutics
(
Get Free Report)
Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.
Further Reading
Before you consider Mineralys Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mineralys Therapeutics wasn't on the list.
While Mineralys Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
